Raw data from 'CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies'

This study aimed to investigate mechanisms of rituximab (RTX) resistance in diffuse large B-cell lymphoma (DLBCL), with a focus on the regulation of CD37 expression. For this purpose, RTX-resistant B-cell lymphoma cell lines were generated as in vitro models. The study evaluated how changes in CD37 expression influence the efficacy of CD37-targeted therapies, including monoclonal antibodies and CAR T cells, and assessed whether CD37 remains a viable therapeutic target in the context of RTX resistance.The dataset includes:Derivation of rituximab (RTX) resistance in two cell lines, SU-DHL4 and Raji, which were used for experiments in the main body and supplementary materials of the related publication. The data contain flow cytometry readouts from complement-dependent cytotoxicity assays performed during consecutive passages with rituximab and human serum, showing how resistance was established in these cell lines.Flow cytometry readouts from cytotoxicity assays involving CD37 CAR-T cells, processed for Figure 5A and 5B of the related publication.